HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 48.6%

Neg 48.6% Neu 0% Pos 0%

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $22 to $15.